Recruiting Cancer Clinical Trials

Catalina-2

A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF TORL-1-23 IN WOMEN WITH ADVANCED PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER (INCLUDING PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCERS) EXPRESSING CLAUDIN 6
Description: This Phase 2 study has been designed to further evaluate the safety, tolerability, and efficacy of TORL-1-23 in women with platinum-resistant ovarian cancer (PROC) whose tumors express CLDN6.
Study Phase: Phase 2
Principal Investigator: Prof Karen Cadoo
Further information

RAMP-301 VS-6766-301

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (GOG-3097; ENGOT-ov81/NCRI)
Description: This trial is for patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC), which compares a combination therapy of Avutometinib plus Defactinib versus Investigator’s Choice of Treatment.
Study Phase: Phase 3
Principal Investigator:
Further information